Brief: Pharvaris Says Positive Phase 2 Data From Rapide-1 Study Of Phvs416 For On-Demand Treatment Of HAE Attacks Highlighted At 2023 HAEi Regional Conference Apac
18/03/2023 04:37
March 18 (Reuters) - Pharvaris NV PHVS.O :
* PHARVARIS NV-POSITIVE PHASE 2 DATA FROM RAPIDE-1 STUDY OF
PHVS416 FOR ON-DEMAND TREATMENT OF HAE ATTACKS HIGHLIGHTED AT
2023 HAEI REGIONAL CONFERENCE APAC
Source text for Eikon: ID:nGNXbv42hh
Further company coverage: PHVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharvaris
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Pharvaris gains after genetic disorder drug meets late-stage trial goal